President Donald Trump signed an executive order Saturday directing federal agencies to accelerate research into psychedelic drugs, a move he said came after podcast host Joe Rogan sent him a text message making the case for ibogaine as a treatment for veterans battling post-traumatic stress disorder and addiction.
The signing took place in the Oval Office on April 18, with Rogan standing alongside Trump, Health and Human Services Secretary Robert F. Kennedy Jr., Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and former Navy SEAL Marcus Luttrell, a combat veteran who told the president the treatment changed his life.
The order directs the Food and Drug Administration to expedite breakthrough therapy designations for certain psychedelics, encourages interagency data sharing, and opens the door to rapid scheduling changes if safety and efficacy are demonstrated. No psychedelic has yet received FDA approval in the United States. The directive marks the most aggressive federal step yet toward removing the regulatory barriers that have kept substances like ibogaine and LSD classified as Schedule I drugs under federal law.
Rogan described the exchange with Trump in blunt terms. Fox News reported that Rogan told the Oval Office gathering he had shared information with the president claiming ibogaine was highly successful in treating opiate addiction. Trump's reply, Rogan said, was immediate.
"The text message came back: 'Sounds great. Do you want FDA approval? Let's do it.'"
Rogan added: "It was literally that quick."
Trump confirmed the account during the event, praising Rogan's role while noting their political differences with a light touch.
"Joe is an amazing guy. He wrote me a little note about this, and I had it checked out. Everybody came back with the same answer."
He added: "We all respect Joe and he's a little bit more liberal than I am. That's OK. I have a lot of friends that are liberal."
Trump's willingness to act on a direct personal appeal, and to credit the person who made it, is a reminder of how this president operates. He has long cultivated relationships across the political and media landscape, from allies in his broader orbit to figures who don't share his politics but share his interest in getting results.
The administration framed the order squarely around military veterans suffering from PTSD, traumatic brain injuries, and addiction, populations that have waited years for treatments the federal bureaucracy has been slow to evaluate.
Trump stated the case plainly during the signing:
"In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans."
Marcus Luttrell, the former Navy SEAL and author of "Lone Survivor," offered the most personal testimony. He told Trump directly that psychedelic-assisted treatment had transformed his life after years of struggling with the aftermath of combat.
"It absolutely changed my life for the better."
Luttrell added: "You're going to save a lot of lives through it."
The Washington Examiner reported that Trump cited a Stanford study showing major reductions in depression and anxiety symptoms among special operations veterans who received psychedelic-assisted therapy. Rogan, for his part, explained that he had interviewed veterans on his podcast who described life-changing experiences with ibogaine, and that millions of listeners heard those stories firsthand.
That kind of grassroots, bottom-up pressure, veterans telling their own stories to a massive audience, then a media figure carrying that message directly to the president, is exactly the kind of thing Washington's institutional gatekeepers tend to resist. For years, the regulatory apparatus treated psychedelics as politically untouchable, even as the evidence mounted and the veteran suicide crisis deepened.
The executive order takes several concrete steps. It directs the FDA to fast-track breakthrough therapy designations for psychedelics that have already shown promise. It encourages federal agencies to share data across bureaucratic silos. And it opens a pathway for rapid rescheduling if clinical evidence supports it.
Newsmax reported that the FDA plans to issue national priority vouchers for three psychedelics and is taking steps toward the first-ever human trials of ibogaine in the United States, a development that has been stalled for years by regulatory caution and ibogaine's Schedule I classification.
Ibogaine, derived from a West African shrub, has drawn particular attention, and particular controversy. Existing medical literature has linked the substance to more than 30 deaths. Frederick Barrett of Johns Hopkins University acknowledged the challenge in remarks attributed to PBS.
"It's been incredibly difficult to study ibogaine in the US because of its known cardiotoxicity."
But Barrett also said the executive order could open the door to the kind of rigorous research that has been nearly impossible under the current framework: "If the executive order can pave the way for doing objective, scientific research with this compound, it would help us understand whether it is truly a better psychedelic therapy than others."
That tension, between known risks and the potential for breakthrough treatments, is precisely why the federal government's default posture of inaction has been so costly. Veterans who have exhausted every conventional option deserve to know whether these therapies work, and the only way to find out is through the kind of accelerated, well-designed research this order is meant to enable.
Two states, Oregon and Colorado, have already legalized supervised psilocybin therapy programs. The federal government has been conspicuously behind the curve. Trump's willingness to act decisively where others have hesitated is a pattern, and it is one that tends to produce results even when the establishment wrings its hands.
The order did not materialize overnight. HHS Secretary Robert F. Kennedy Jr. led months of internal discussions on expanding access to alternative mental health treatments. Mehmet Oz described the internal effort as a rapid policy sprint. The groundwork was already being laid inside the administration when Rogan's outreach appears to have accelerated the timeline.
Rogan told the gathering that his involvement grew out of conversations on his podcast, where veterans and researchers described the potential of psychedelic-assisted therapy. As the New York Post reported, Rogan has been a high-profile advocate for ibogaine research and had featured veterans on his show who credited the drug with saving their lives.
The combination of Kennedy's institutional work and Rogan's public advocacy created a moment where the policy and the politics aligned. That Rogan, a figure who defies easy partisan classification, was willing to stand in the Oval Office and put his credibility behind the effort says something about where this issue sits. It is not a left-right fight. It is a fight between people who want answers and a bureaucracy that has been content to wait.
Trump, for his part, made clear he saw no contradiction in working with someone who doesn't share all his political views. That kind of pragmatism, focusing on outcomes rather than tribal loyalty, is what critics across the aisle rarely give this administration credit for.
The executive order is a directive, not a final answer. The FDA still has to act. Clinical trials still have to be designed, funded, and completed. Ibogaine's cardiotoxicity risks are real and must be addressed through rigorous science, not wishful thinking. The 30-plus deaths linked to the substance in existing literature cannot be hand-waved away.
But the status quo, where Schedule I classification makes serious research nearly impossible, where veterans cycle through failed treatments while the bureaucracy moves at its own pace, where promising therapies are available in other countries but not here, is itself a form of harm. Every month of delay is another month that men and women who served this country are left without options that might work.
Trump said it directly: "Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life." Whether the FDA follows through with the urgency the order demands will be the real measure of success.
Kennedy's $100 million effort to address addiction, homelessness, and mental illness provides additional institutional backing. The question now is whether the federal health bureaucracy will match the pace that this administration expects, or whether the same institutional inertia that has stalled psychedelic research for decades will quietly reassert itself once the cameras leave the Oval Office.
When a combat veteran tells the president of the United States that a treatment saved his life, and the president acts on it the same week a podcast host sends a text, that is government moving at the speed of common sense. The question is whether the rest of Washington can keep up.
